iTeos Therapeutics (NASDAQ:ITOS) Issues Earnings Results

iTeos Therapeutics (NASDAQ:ITOS) announced its quarterly earnings data on Wednesday. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.13, Zacks reports.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS opened at $7.26 on Thursday. The firm’s 50 day moving average price is $7.54 and its 200-day moving average price is $9.55. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75. The company has a market cap of $265.24 million, a PE ratio of -2.30 and a beta of 1.38.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ITOS shares. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday. Wells Fargo & Company lowered their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a research note on Thursday, January 16th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.